Amneal Pharmaceuticals Reports Strong 2024 Financial Growth

Amneal Pharmaceuticals ( (AMRX) ) has provided an announcement.

Amneal Pharmaceuticals reported its financial results for the fourth quarter and full year of 2024, showing significant growth across all business segments. The company achieved a net revenue of $2.79 billion for the year, a 17% increase from 2023, driven by new product launches and growth in its Affordable Medicines, AvKARE, and Specialty segments. Despite a GAAP net loss of $117 million for the year, Amneal’s adjusted EBITDA increased by 12% to $627 million. The company also provided its 2025 financial guidance, projecting net revenue between $3.0 billion and $3.1 billion and adjusted EBITDA between $650 million and $675 million, indicating continued expansion in high-growth areas such as Specialty, Biosimilars, and GLP-1 therapies.

More about Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc., headquartered in Bridgewater, NJ, is a global biopharmaceutical company that develops, manufactures, and distributes a diverse portfolio of over 280 pharmaceutical products primarily in the United States. The company operates in three segments: Affordable Medicines, which includes injectables and biosimilars; Specialty, focusing on branded pharmaceuticals for central nervous system and endocrine disorders; and AvKARE, a distributor for the U.S. federal government, retail, and institutional markets.

YTD Price Performance: 7.99%

Average Trading Volume: 1,222,098

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $2.6B

For a thorough assessment of AMRX stock, go to TipRanks’ Stock Analysis page.